2-bromo-5-ethoxy-3-methylpyridine | 1509949-25-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-bromo-5-ethoxy-3-methylpyridine
• 英文别名: 2-Bromo-5-ethoxy-3-methylpyridine
• CAS: 1509949-25-0
• 化学式: C₈H₁₀BrNO
• 分子量: 216.077
• InChiKey: SBONBHTVSZJIHA-UHFFFAOYSA-N

物化性质

• 沸点：
  282.7±35.0 °C(Predicted)
• 密度：
  1.388±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-bromo-5-ethoxy-3-methylpyridine 在 tris-(dibenzylideneacetone)dipalladium(0) 、 盐酸羟胺 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 N,N-二异丙基乙胺 、 sodium t-butanolate 作用下， 以 乙醇 、 二氯甲烷 、 水 、 甲苯 为溶剂， 反应 34.75h， 生成 (S)-5-(1,1-difluoroethyl)-3-(4-(5-ethoxy-3-methylpyridin-2-yl)-2-methylpiperazin-1-yl)-1,2,4-oxadiazole
  参考文献：
  名称：

  Piperazine Oxadiazole Inhibitors of Acetyl-CoA Carboxylase

  摘要：

  Acetyl-CoA carboxylase (ACC) is a target of interest for the treatment of metabolic syndrome. Starting from a biphenyloxadiazole screening hit, a series of piperazine oxadiazole ACC inhibitors was developed. Initial pharmacokinetic liabilities of the piperazine oxadiazoles were overcome by blocking predicted sites of metabolism, resulting in compounds with suitable properties for further in vivo studies. Compound 26 was shown to inhibit malonyl-CoA production in an in vivo pharmacodynamic assay and was advanced to a long-term efficacy study. Prolonged dosing with compound 26 resulted in impaired glucose tolerance in diet-induced obese (DIO) CS7BL6 mice, an unexpected finding.

  DOI：

  10.1021/jm401601s
• 作为产物：
  描述：

  2-溴-5-羟基-3-甲基吡啶 、 碘乙烷 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以95%的产率得到2-bromo-5-ethoxy-3-methylpyridine
  参考文献：
  名称：

  Piperazine Oxadiazole Inhibitors of Acetyl-CoA Carboxylase

  摘要：

  Acetyl-CoA carboxylase (ACC) is a target of interest for the treatment of metabolic syndrome. Starting from a biphenyloxadiazole screening hit, a series of piperazine oxadiazole ACC inhibitors was developed. Initial pharmacokinetic liabilities of the piperazine oxadiazoles were overcome by blocking predicted sites of metabolism, resulting in compounds with suitable properties for further in vivo studies. Compound 26 was shown to inhibit malonyl-CoA production in an in vivo pharmacodynamic assay and was advanced to a long-term efficacy study. Prolonged dosing with compound 26 resulted in impaired glucose tolerance in diet-induced obese (DIO) CS7BL6 mice, an unexpected finding.

  DOI：

  10.1021/jm401601s

文献信息

• [EN] PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF<br/>[FR] DÉRIVÉS DE PYRROLIDINE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET UTILISATIONS ASSOCIÉES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014114578A1

  公开（公告）日：2014-07-31

  The invention relates to new pyrrolidine derivatives of the formula (I), to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  这项发明涉及公式（I）的新吡咯烷衍生物，其用作药物，用于其治疗用途的方法以及含有它们的药物组合物。
• PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2948442B1

  公开（公告）日：2016-10-26
• US8877741B2
  申请人：——

  公开号：US8877741B2

  公开（公告）日：2014-11-04
• Piperazine Oxadiazole Inhibitors of Acetyl-CoA Carboxylase
  作者：Matthew P. Bourbeau、Aaron Siegmund、John G. Allen、Hong Shu、Christopher Fotsch、Michael D. Bartberger、Ki-Won Kim、Renee Komorowski、Melissa Graham、James Busby、Minghan Wang、James Meyer、Yang Xu、Kevin Salyers、Mark Fielden、Murielle M. Véniant、Wei Gu

  DOI：10.1021/jm401601s

  日期：2013.12.27

  Acetyl-CoA carboxylase (ACC) is a target of interest for the treatment of metabolic syndrome. Starting from a biphenyloxadiazole screening hit, a series of piperazine oxadiazole ACC inhibitors was developed. Initial pharmacokinetic liabilities of the piperazine oxadiazoles were overcome by blocking predicted sites of metabolism, resulting in compounds with suitable properties for further in vivo studies. Compound 26 was shown to inhibit malonyl-CoA production in an in vivo pharmacodynamic assay and was advanced to a long-term efficacy study. Prolonged dosing with compound 26 resulted in impaired glucose tolerance in diet-induced obese (DIO) CS7BL6 mice, an unexpected finding.